Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Leukemia|December 22, 2019
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironmentEkaterina Kim, Elisa Ten Hacken, Mariela Sivina, et al.
Blood|September 21, 2019
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapyPhilip A Thompson, Jaya Srivastava, Christine Peterson, et al.
Blood|September 27, 2018
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemiaLisa S Chen, Prithviraj Bose, Nichole D Cruz, et al.
Leukemia|May 3, 2023
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRDPhilip A Thompson, Michael J Keating, Alessandra Ferrajoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation FailureUri Rozovski, Ohad Benjamini, Preetesh Jain, et al.
Leukemia|August 8, 2022
A phase two study of high dose blinatumomab in Richter's syndromePhilip A Thompson, Xianli Jiang, Pinaki Banerjee, et al.
Haematologica|March 18, 2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemiaKerry A Rogers, Philip A Thompson, John N Allan, et al.
Pageof 7